Rezolute shares are down nearly 80% in December after their Phase 3 study for ersodetug missed its primary endpoint. The trial was testing the drug for congenital hyperinsulinism. While the highest dose reduced hypoglycemia events by 45%, the placebo group also saw a 40% improvement, so the results weren't statistically significant. The study also missed its secondary endpoint for time spent in hypoglycemia. The company says they are reviewing the data and plan to meet with the FDA to discuss next steps. They are also continuing a separate study for tumor-induced HI with data expected in 2026.